Ralliant Corporation $RAL Stake Boosted by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its stake in Ralliant Corporation (NYSE:RAL) by 60.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,314,834 shares of the company’s stock after acquiring an additional 496,171 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Ralliant were worth $54,669,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of RAL. Danske Bank A S acquired a new stake in Ralliant during the fourth quarter valued at $25,000. V Square Quantitative Management LLC acquired a new position in Ralliant in the 4th quarter worth about $26,000. Allworth Financial LP raised its stake in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares in the last quarter. Palisade Asset Management LLC purchased a new stake in shares of Ralliant during the 3rd quarter worth about $26,000. Finally, BOKF NA acquired a new stake in shares of Ralliant during the 3rd quarter valued at about $29,000.

Ralliant Stock Down 1.8%

RAL opened at $65.78 on Friday. The business has a 50 day moving average price of $67.20 and a 200 day moving average price of $54.34. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $75.41. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.05 and a current ratio of 1.52. The firm has a market cap of $7.36 billion and a P/E ratio of -6.06.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. The company had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Research analysts forecast that Ralliant Corporation will post 2.88 EPS for the current year.

Ralliant Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is presently -1.83%.

Ralliant News Roundup

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Quarterly results exceeded expectations: Ralliant reported second-quarter revenue of approximately $568 million, up 13% year over year, and adjusted EPS of $0.68 versus the $0.63 consensus estimate. Adjusted net earnings were $76 million, while net earnings were $57 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Full-year and third-quarter outlooks topped consensus: Ralliant guided third-quarter EPS to $0.72-$0.78 and revenue to $570 million-$590 million, above analyst estimates of $0.68 and $556.4 million, respectively. Full-year 2026 adjusted EPS guidance was raised to $2.76-$2.90 from an analyst consensus of $2.65, with revenue expected around $2.25 billion-$2.30 billion. Ralliant forecasts 2026 revenue and productivity savings
• Positive Sentiment: Cost-reduction efforts could support future margins: Ralliant’s enterprise productivity program is targeting $50 million-$60 million in annualized run-rate savings by 2028, providing a potential boost to earnings and cash flow.
• Positive Sentiment: Analysts raised targets: Citigroup increased its target to $82 and initiated a “buy” rating, Truist raised its target to $82 while reaffirming “buy,” and RBC lifted its target to $73 while maintaining a “sector perform” rating. These targets imply meaningful upside from the recent trading level. Benzinga analyst actions
• Neutral Sentiment: Trading volatility increased: RAL experienced a temporary limit-up/limit-down trading pause during the earnings session, signaling elevated short-term volatility rather than a fundamental change in the business.
• Negative Sentiment: Valuation and execution risks remain: Despite the adjusted earnings beat, investors may continue to focus on Ralliant’s reported profitability, integration or productivity-program execution, and the gap between the stock’s recent price and analyst targets.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Wall Street Zen cut Ralliant from a “buy” rating to a “hold” rating in a research note on Sunday, July 26th. Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price for the company. in a research note on Wednesday, May 27th. Oppenheimer boosted their target price on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Truist Financial restated a “buy” rating and set a $82.00 price target (up from $68.00) on shares of Ralliant in a research note on Friday. Finally, Evercore assumed coverage on shares of Ralliant in a report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $75.70.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.